FWM
ABVX

Focused Wealth Management’s Abivax ABVX Stock Holding History

Focused Wealth Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$47.6K – 229
2025
Q4 		$47.6K Buy
+400
New +$43.6K 0.01% 209

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Focused Wealth Management's ABVX Position: Q1 2026 in Review

Focused Wealth Management sold out of Abivax (ABVX) in Q1 2026, closing a stake of 1,200 shares — an estimated $162K sold.

Focused Wealth Management first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $162K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Focused Wealth Management reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Focused Wealth Management sold 1,200 Abivax shares in Q1 2026, an estimated $162K.
  • Focused Wealth Management first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
  • Focused Wealth Management's Abivax position peaked at $162K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Focused Wealth Management's 13F filing for Q1 2026, filed 20 Apr 2026.